86. Pulmonary arterial hypertension Clinical trials / Disease details
Clinical trials : 1,181 / Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-003975-38-NL (EUCTR) | 18/02/2008 | 17/10/2007 | Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH | Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH | Pulmonary arterial hypertension MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension | Product Name: Terguride 0,5mg tablet INN or Proposed INN: Terguride Other descriptive name: Transdihydrolisuride | Ergonex Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 84 | Phase 2 | Czech Republic;Germany;Netherlands;Austria | ||
| 2 | EUCTR2007-003975-38-DE (EUCTR) | 22/11/2007 | 28/08/2007 | Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH | Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH | Pulmonary arterial hypertension MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension | Product Name: Terguride 0,5mg tablet INN or Proposed INN: Terguride Other descriptive name: Transdihydrolisuride | Ergonex Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 99 | Phase 2 | Czech Republic;Austria;Netherlands;Germany |